Last reviewed · How we verify
Linaclotide 72 micrograms
Linaclotide is a guanylate cyclase-C (GC-C) agonist that increases intracellular cyclic GMP in intestinal epithelial cells, promoting fluid secretion and accelerating intestinal transit.
Linaclotide is a guanylate cyclase-C (GC-C) agonist that increases intracellular cyclic GMP in intestinal epithelial cells, promoting fluid secretion and accelerating intestinal transit. Used for Chronic idiopathic constipation, Irritable bowel syndrome with constipation (IBS-C).
At a glance
| Generic name | Linaclotide 72 micrograms |
|---|---|
| Sponsor | Md Mehedi Shahriar |
| Drug class | Guanylate cyclase-C agonist |
| Target | GC-C (guanylate cyclase-C receptor) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
By activating GC-C receptors on the apical surface of intestinal epithelial cells, linaclotide increases cGMP levels, which opens cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels and promotes water secretion into the intestinal lumen. This increases stool frequency and softens stool consistency, providing relief from constipation and associated abdominal discomfort.
Approved indications
- Chronic idiopathic constipation
- Irritable bowel syndrome with constipation (IBS-C)
Common side effects
- Diarrhea
- Abdominal pain
- Abdominal distension
- Nausea
- Headache
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Linaclotide 72 micrograms CI brief — competitive landscape report
- Linaclotide 72 micrograms updates RSS · CI watch RSS
- Md Mehedi Shahriar portfolio CI